Physician profile
Jodan Pathinathan
NPI 1780112896
$3,150.21
in general payments reported to CMS, 2019-2025
19 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $395 · 2023: $796 · 2024: $699 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,755.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $474.91 | 2023-2025 | Austedo Xr, Austedo Xr |
| Genzyme Corporation | $379.11 | 2023-2024 | |
| Axsome Therapeutics, INC. | $341.61 | 2024-2025 | Auvelity, Symbravo |
| Abbvie INC. | $250.83 | 2025 | |
| Alkermes, INC. | $243.39 | 2023-2025 | Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $229.65 | 2022 | |
| Vanda Pharmaceuticals INC. | $221.67 | 2024 | Fanapt |
| Kestra Medical Technology Services, INC. | $216.09 | 2024-2025 | Assure Wcd |
| Eisai INC. | $125.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2023 | Dupixent |
| Otsuka America Pharmaceutical, INC. | $115.80 | 2025 | Rexulti |
| Neurelis, INC. | $85.85 | 2022 | |
| Sk Life Science, INC. | $62.04 | 2022 | |
| Alk-Abello, INC | $50.00 | 2023 | Odactra, Ragwitek, Grastek |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $36.31 | 2025 | Collagenase Santyl |
| Janssen Pharmaceuticals, INC | $25.42 | 2024 | Xarelto |
| Pfizer INC. | $25.00 | 2025 | |
| Horizon Therapeutics Plc | $17.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodan Pathinathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.